Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, has received final approval from the United States (US) Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for bupropion hydrochloride extended-release tablets, 300 mg.
Bupropion hydrochloride extended-release is the generic equivalent to GlaxoSmithKline's Wellbutrin XL tablets, which is indicated for the treatment of major depressive disorder. The company intends to launch the product immediately.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.